Le Lézard
Classified in: Health, Science and technology
Subjects: BFA, FDA

CASIO OBTAINS U.S. FDA CLEARANCE FOR DERMOCAMERAtm AND SCOPE FOR SKIN OBSERVATION


DOVER, N.J., Feb. 15, 2022 /PRNewswire/ -- Casio America, Inc., announced today that the U.S. Food and Drug Administration (FDA) has cleared the DZ-D100 DERMOCAMERAtm and the DZ-S50 scope for skin observation as medical devices. The DZ-D100 and DZ-S50 will be available in the U.S. on Casio America's e-commerce site by March 2022.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/9008951-casio-obtains-us-fda-clearance-dermocamera-scope-skin-observation/

 

Casio began providing the DZ-D100 in Japan in May 2019. The DZ-D100 was developed in collaboration with dermatology professionals and delivers both standard sized and close-up shots of an affected area with a single unit, and can be used with the D'z IMAGE Viewer, a free downloadable software to manage the captured images.

In March 2020, Casio released the DZ-S50 scope, making skin observation even easier. Medical professionals who have introduced these devices in their practice have provided positive feedback, commenting that these Casio products make it simple to take both ordinary or standard sized and close-up shots without switching lenses and noting the ease of making observations since the unit can capture polarized, non-polarized and UV* photos at the same viewpoint with a single click of the shutter button. Casio has been rolling out these innovative medical devices aggressively in markets outside Japan, starting with the launch in Australia and New Zealand in February 2021, where there are high rates of skin disease among the population.

* A 405 nm safelight wavelength is used.

The marketing of certain medical devices in the U.S. requires FDA clearance. The DZ-D100 and DZ-S50 have received FDA Class I clearance. Class I medical devices are devices with low or moderate risk to patient health and safety.

Casio will continue expanding and developing its medical device business both in and outside Japan, seeking to contribute to medical treatment around the world.

About Casio America, Inc.
Casio America, Inc., Dover, N.J., is the U.S. subsidiary of Casio Computer Co., Ltd., Tokyo, Japan, one of the world's leading manufacturers of consumer electronics and business equipment solutions. Established in 1957, Casio America, Inc. markets calculators, keyboards, digital cameras, mobile presentation devices, disc title and label printers, watches, cash registers and other consumer electronic products. Casio has strived to fulfill its corporate creed of "creativity and contribution" through the introduction of innovative and imaginative products. For more information, visit www.casio.com.

 

DZ-D100 DERMOCAMERAtm

 

D'Z IMAGE VIEWER

 

DZ-S50 DERMOSCOPE

 

DERMOCAMERA

 

DZ-D100'S RING LIGHT

 

SOURCE Casio America, Inc.


These press releases may also interest you

at 07:13
Webblogic®, a pioneer in medical device manufacturing technology, is set to launch its comprehensive range of advanced manufacturing and packaging equipment specifically designed for the Medical Device, Pharma, and Life Sciences industries. In...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...



News published on and distributed by: